BioRestorative Therapies (BRTX) Investor presentation summary

Business overview and leadership

• Focuses on regenerative medicine with programs in spine, metabolic, and cosmetic therapies.

• Pipeline includes BRTX-100 (spine), ThermoStem (metabolic), and biocosmeceuticals (cosmetic applications).

• Leadership team has extensive experience in healthcare, investment banking, and cell therapy R&D.

• Scientific advisory board includes experts from Harvard, Northwell Health, and other leading institutions.

Product pipeline and clinical development

• BRTX-100 is an autologous, hypoxic-cultured, bone marrow-derived MSC therapy for chronic lumbar disc disease (CLDD), in Phase 2 trials.

• ThermoStem targets metabolic disorders using brown adipose-derived stem cells, with preclinical proof of concept and patent portfolio.

• Biocosmeceuticals leverage exosome and growth factor biologics for cosmetic and hair growth applications.

• Robust preclinical and clinical pipeline covers spine, musculoskeletal, metabolic, and cosmetic indications.

Clinical and market highlights

• BRTX-100 offers a minimally invasive, single-injection alternative to costly and invasive spine surgeries.

• Phase 2 trial design includes 99 subjects, with primary endpoints of function and pain improvement at 12 and 24 months.

• Preliminary Phase 2 data show meaningful improvements in pain and function, meeting FDA thresholds for advancement.

• Large addressable market for CLDD, with millions affected and high annual surgical costs in the U.S.